Pricing, patents and the PMPRB in Canada

The price of patented medicines in Canada is regulated by the Patented Medicine Prices Review Board (PMPRB), an independent, quasi-judicial body established under the Patent Act to ensure the prices of patented medicines are not excessive.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Canada's drug pricing plan prompts backlash

26 October 2020 The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.

Americas

Generics in Canada: The race for market exclusivity

3 March 2015 Section 8 of Canada’s Patented Medicines (Notice of Compliance) Regulations is a unique provision under which an innovator can be liable for a generic’s losses that result from a delay in coming to market, as Gunars Gaikis explains

More on this story

Americas

Canada's drug pricing plan prompts backlash

26 October 2020 The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.

Americas

Generics in Canada: The race for market exclusivity

More on this story

Americas

Canada's drug pricing plan prompts backlash

26 October 2020 The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.

Americas

Generics in Canada: The race for market exclusivity